Relmada Therapeutics Stock News

CORAL GABLES, Fla., Feb. 10, 2022 /PRNewswire/ -- Relmada Therapeutics, Inc. (NASDAQ: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced that Sergio Traversa, Chief Executive Officer, and Maged Shenouda, Chief Financial

RLMD is set to produce results in 2022 from four clinical trials of REL-1017, its novel antidepressant. Late-stage failures of antidepressants are not unheard of, so I provide a cautionary tale to RLM

The mean of analysts' price targets for Relmada Therapeutics, Inc. (RLMD) points to a 231.4% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agre

For years, one of the most dependable sectors, especially for investors who are more conservative, was health care.

Relmada Therapeutics had its price objective decreased by SVB Leerink from $50.00 to $42.00 in a research report sent to investors on Monday morning, PriceTargets.com reports…

Equities analysts forecast that Relmada Therapeutics, Inc. (NASDAQ:RLMD) will post earnings per share (EPS) of ($1.87) for the current fiscal quarter, Zacks Investment Research reports. Zero analysts have provided estimates for Relmada Therapeutics earnings. The lowest EPS estimate is ($1.96) and the highest is ($1.79). Relmada Therapeutics reported earnings per share of ($1.28) in the []

Wall Street analysts expect Relmada Therapeutics, Inc. (NASDAQ:RLMD) to report earnings per share of ($1.87) for the current fiscal quarter, according to Zacks Investment Research. Zero analysts have issued estimates for Relmada Therapeutics earnings, with the highest EPS estimate coming in at ($1.79) and the lowest estimate coming in at ($1.96). Relmada Therapeutics reported earnings []

Relmada Therapeutics Inc (NASDAQ: RLMD) priced an upsized underwritten public offering of 8.82 million shares at $17.00 per share, with gross proceeds of approximately $150 million.  The offer pric

CORAL GABLES, Fla., Dec. 8, 2021 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced the pricing of an upsized underwritten public offering of 8,823,530 shares of its common

CORAL GABLES, Fla., Dec. 08, 2021 (GLOBE NEWSWIRE) -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a late-stage biotechnology company addressing diseases of the central nervous system (CNS), today announced its intention to offer and sell $100 million of shares of its common stock in an underwritten public offering pursuant to its existing shelf registration statement. Relmada also intends to grant the underwriters a 30-day option to purchase up to an additional 15% of the shares of its common stock offered in the public offering on the same terms and conditions. The offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed or as to the size or terms of the offering.

Equities analysts forecast that Relmada Therapeutics, Inc. (NASDAQ:RLMD) will announce earnings per share of ($1.87) for the current fiscal quarter, Zacks reports. Zero analysts have provided estimates for Relmada Therapeutics’ earnings. The highest EPS estimate is ($1.79) and the lowest is ($1.96). Relmada Therapeutics posted earnings of ($1.28) per share during the same quarter last […]

Zacks Investment Research downgraded shares of Relmada Therapeutics (NASDAQ:RLMD) from a hold rating to a sell rating in a report issued on Wednesday morning, Zacks.com reports. According to Zacks, Relmada Therapeutics Inc. is a clinical stage, public specialty pharmaceutical company. The Company is developing LevoCap ER, an abuse resistant, once-a-day sustained release dosage form of []

Northern Trust Corp reduced its position in shares of Relmada Therapeutics, Inc. (NASDAQ:RLMD) by 3.9% in the second quarter, Holdings Channel reports. The firm owned 156,398 shares of the companys stock after selling 6,296 shares during the period. Northern Trust Corps holdings in Relmada Therapeutics were worth $5,006,000 at the end of the most recent []